| Literature DB >> 31765388 |
Amanda Xavier1, Heloize Oliveira1,2, Ana Aguiar-Santos3, Walter Barbosa Júnior3, Ellyda da Silva3, Cynthia Braga3, Cristine Bonfim4,5, Zulma Medeiros1,3.
Abstract
BACKGROUND: The objective of the Global Program to Eliminate Lymphatic Filariasis (GPELF) is to phase out this endemic disease as a public health problem by 2020. Validation of elimination is obtained from the World Health Organization through evidence of non-transmission in countries that have already been subjected to mass drug administration (MDA) and in places adjoining these endemic areas. While three municipalities in Brazil have completed MDA, the epidemiological situation remains uncertain in nine adjoining municipalities. To determine the epidemiological status, this study was to perform a review of the literature and a school-based survey to describe the past and recent endemicity of lymphatic filariasis (LF) theses nine municipalities in Brazil. METHODOLOGY/PRINCIPLEEntities:
Mesh:
Substances:
Year: 2019 PMID: 31765388 PMCID: PMC6917295 DOI: 10.1371/journal.pntd.0007836
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1Territorial map and demographic information for the research areas.
Municipalities with uncertain and endemic areas for lymphatic filariasis.
Fig 2Landmarks in the evolution of epidemiology and entomological surveys in Pernambuco.
Autochthonous cases, filarial morbidity cases, and vector tests from municipalities in Pernambuco.
| Surveys | Human | Vector | Morbidity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| References | Population | Methods | No. tests | No. infected | No. tests (house/female mosquitoes) | % infected | ADLA | Hydrocele | Cloudy urine | Elephantiasis | |||
| Thick drop | ICT | Autochthonous | Allochthonous | NI | |||||||||
| [ | Soldiers >18 years | Prevalence study | 23,773 | 01¹ | |||||||||
| [ | General population | Prevalence study | 2,829 | 03 | |||||||||
| [ | General population | Prevalence study | 23,773 | 012 | |||||||||
| [ | General population | Prevalence study | 7,650 | 01³ | 055 | 80 | 20 | 02 | 07 | ||||
| [ | General population | Prevalence study | 1,554 | 026 | |||||||||
| [ | Prevalence study | 23,773 | 044 | ||||||||||
| [ | General population | Prevalence study | 3,164 | 12 | |||||||||
| [ | General population | Prevalence study | 72 | -- | -- | -- | |||||||
| [ | General population | Prevalence study | 05 | 087 | |||||||||
| [ | General population | Prevalence study | 2,358 | 05 | |||||||||
| [ | General population | Prevalence study | 960 | -- | -- | -- | |||||||
| [ | General population | Prevalence study | 54 | -- | -- | -- | |||||||
| [ | General population | Prevalence study | 2,513 | 028 | 43 | 15 | -- | 01 | |||||
| [ | General population and female | Prevalence study | 2,459 | 17 | 356/ 754 | 1.1 | |||||||
| [ | General population | Prevalence study | 1,985 | 05 | |||||||||
*total research sample, independent of the municipality;
** ADLA = acute dermatolymphangioadenitis;
*** NI- No information; Autochthonous—subject who always lived in the same neighborhood. 1- Caetes neighborhood; 2—Ponte dos Carvalhos district; 3—Pontezinha district 4- neighborhood: 2 from Fabrica, 1 case from dos Estados and 1 from Bairro Novo; 5- from Recife and Jaboatão dos Guararapes; 6- from Recife; 7- from Recife, Jaboatão dos Guararapes and Olinda; 8- from Recife
Fig 3Spatial distributions of the examined schools.
The spatial distributions of the schools included in the survey were homogeneous in all urban areas of Abreu e Lima, Cabo de Santo Agostinho, Camaragibe, Igarassu, Ilha de Itamaracá, Ipojuca, Itapissuma, Moreno, and São Lourenço da Mata.
Distribution of schoolchildren in the municipalities participating in the survey, according to age, sex, and test results, 2016.
| Districts | Abreu e Lima | Cabo de Santo Agostinho | Camaragibe | Igarassu | Ilha de Itamaracá | Ipojuca | Itapissuma | Moreno | São Lourenço da Mata | |
|---|---|---|---|---|---|---|---|---|---|---|
| Results | ||||||||||
| 8,134 | 15,400 | 12,283 | 8,458 | 1,492 | 7,100 | 2,206 | 4,756 | 9,328 | ||
| 22 | 32 | 25 | 24 | 13 | 21 | 09 | 13 | 26 | ||
| 1,767 | 3,138 | 2,870 | 1,387 | 666 | 3,176 | 833 | 974 | 2,411 | ||
| 597–33,79% | 946–30,15% (28.54–31.76) | 993–34,60% | 578–41,67% | 167–25,08% | 1,270–39,99% (38.29–41.69) | 272 (32,65%) | 267 (27,41%) (24.61–30.21) | 1,017 (42,18%) (40.21–44.15) | ||
| 1,170–66,21% | 2,192–69,85% | 1,877–65,40% | 809–58,33% | 499–74,92% | 1,906–60,01% (58.31–61.71) | 561 (67,35%) | 707 (72,59%) (69.79–75.39) | 1,394 (57,82%) (55.85–59.79) | ||
| 864–48,90% | 1,632–52,00% (50.25–53.75) | 1,471–51,25% | 698–50,32% | 340–51,05% | 1,625–53,37% (51.64–55.10) | 399 (47,89%) | 490 (50,30%) (47.16–53.44) | 1,307 (54,20%) (52.21–56.19) | ||
| 903–51,10% | 1,506–48,00% | 1,399–48,75% | 690–49,68% | 326–48,05% | 1,551–48,83% (47.09–50.57) | 432 (52,11%) | 484 (49,70%) (46.56–52.84) | 1,104 (45,80%) (43.81–47.79) | ||
| 09 | 09 | 09 | 09 | 06 | 09 | 07 | 08 | 09 | ||
| 00 (0,00%) | 00 (0,00%) | 01 (0,00%) | 00 (0,00%) | 00 (0,00%) | 00 (0,00%) | 00 (0,00%) | 00 (0,00%) | 00 (0,00%) | ||
CI—Confidence interval
ICT—Immunochromatographic card test